Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Book Volume: 20
Journal Issue: 18
DOI: 10.3390/ijms20184504
Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC), ranks the fourth leading cause of cancer-related deaths in the western world. While the incidence of pancreatic cancer is displaying a rising tendency every year, the mortality rate has not decreased significantly because of late diagnosis, early metastasis, and limited reaction to chemotherapy or radiotherapy. Adjuvant chemotherapy after surgical resection is typically the preferred option to treat early pancreatic cancer. Although 5-fluorouracil/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel can profoundly improve the prognosis of advanced pancreatic cancer, the development of chemoresistance still leads to poor clinical outcomes. Chemoresistance is multifactorial as a result of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment. Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. Therefore, we outline new perspectives for enhancing the efficacy of gemcitabine after reviewing the related factors of gemcitabine metabolism, mechanism of action, and chemoresistance.
APA:
Zeng, S., Pöttler, M., Lan, B., Grützmann, R., Pilarsky, C., & Yang, H. (2019). Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences, 20(18). https://doi.org/10.3390/ijms20184504
MLA:
Zeng, Siyuan, et al. "Chemoresistance in Pancreatic Cancer." International Journal of Molecular Sciences 20.18 (2019).
BibTeX: Download